Literature DB >> 8910812

Hyperthyroidism in children: an Indian experience.

P S Menon1, G R Singh.   

Abstract

During the period 1986-1993, 24 children with hyperthyroidism were referred to us for management. Two of them had factitious hyperthyroidism, one toxic nodular goiter and another neonatal Graves' disease. Twenty children (6M, 14F) had Graves' disease. Their age at presentation was 10.86 +/- 2.02 years and duration of symptoms ranged from 2.5 months to 7 years. Neuropsychiatric manifestations, such as hyperkinesis, irritability, excitability and behavioral problems, were the most common initial presenting symptoms (90%). Goiter of varying grades was present in 18 children. Eye involvement of mild or moderate intensity was present in 85% and cardiac involvement in 30%. Serum free thyroxine and triiodothyronine levels were high and radioactive iodine uptake was elevated. All of them received carbimazole 0.5-0.7 mg/kg in three divided doses. Seventeen responded to therapy over a period of time while three did not. On withdrawal, six of the responders relapsed. Hyperthyroidism in children is rare and when it occurs it is almost always due to Graves' disease. The prominence of neuropsychiatric symptoms, insidious onset and absence of severe infiltrative ophthalmopathy differentiates it from the adult type of disease. Prolonged medical therapy is needed to induce good continued remission.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910812     DOI: 10.1515/jpem.1996.9.4.441

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  2 in total

1.  Juvenile Graves' disease with opthalmopathy, lymphadenopathy, accelerated growth and congestive cardiac failure.

Authors:  M K Dutta; Abhay Gundgurthi; M K Garg; N Kotwal
Journal:  Indian J Pediatr       Date:  2011-06-25       Impact factor: 1.967

Review 2.  Neuropsychiatric aspects of pediatric thyrotoxicosis.

Authors:  V S Bhatara; R Sankar
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.